

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AbbVie (venetoclax)	All Wales Therapeutics and Toxicology Centre
 Patient/carer groups African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency for Equality Blood Cancer UK Cancer Black Care Cancer52 Chronic Lymphocytic Leukaemia Support Association Follicular Lymphoma Foundation Helen Rollason Cancer Charity Independent Cancer Patients Voice Kevin Kararwa Leukaemia Trust Leukaemia Cancer Society Leukaemia Care Lymphoma Action Macmillan Cancer Support Maggie's Centres Marie Curie South Asian Health Foundation 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government Comparator companies AstraZeneca UK (acalabrutinib)
South Asian Health Foundation	Baxter Healthcare (cyclophosphamide)
Specialised Healthcare Alliance	Celltrion Healthcare UK (rituximab)
Tenovus Cancer Care	Dr. Reddy's Laboratories UK
WMUK	(bendamustine)
	Janssen-Cilag (a Johnson & Johnson
Healthcare professional groups	Innovative Medicine Company)
Association of Cancer Physicians	(ibrutinib)
British Blood Transfusion Society	Pfizer (rituximab)
British Committee for Standards in	Roche Products (obinutuzumab,
Haematology	rituximab)
British Geriatrics Society	Sandoz (cyclophosphamide, rituximab)

Final stakeholder list for the evaluation of venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Institute of Radiology British Psychosocial Oncology Society British Society for Haematology British Society of Interventional Radiology 	 Sanofi (fludarabine) Seacross Pharmaceuticals (bendamustine) Zentiva (bendamustine)
 Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK CLL Forum UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Relevant research groups Cochrane Haematological Malignancies Group Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
Department of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the evaluation of venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]

Issue date: May 2025



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.